As of November 15, 2026, Zevra Therapeutics, Inc. is a publicly traded company (Nasdaq: ZVRA); its largest reported holder is Fidelity (FMR), with 9.4% on Schedule 13G/A of November 5, 2026, then Woodline Partners LP (8.1%). The largest insider holding is Neil F. McFarlane, the chief executive and president, with 417,225 shares (0.70% of shares outstanding), per Form 4 of October 13, 2026 (Schedule 13G/A, November 5, 2026).
Is this your company?
About to sign with, pay or invest in Zevra Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Zevra Therapeutics, Inc. a real, registered company?
- Zevra Therapeutics Inc files with the SEC under CIK 1434647 (its SEC filings).
- Its shares are listed under the ticker ZVRA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ZEVRA THERAPEUTICS INC in our court records and SEC 8-K records (as of 2026-11-15).
- Leadership changes: the latest reported is Justin Renz, Chief Financial Officer (Form 8-K filed 2026-03-09). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Zevra Therapeutics, Inc.'s owners and officers?
Zevra Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 9.4% |
| Schedule 13G/A, 2026-08-14 | Woodline Partners LP | 8.1% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 8.3% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.11% |
| Schedule 13G, 2026-05-06 | Fmr LLC | 5.5% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2025-11-14 | Woodline Partners LP | 6.2% |
| Schedule 13G/A, 2025-11-13 | Adage Capital Management, L.P. | 3.96% |
Questions about who owns Zevra Therapeutics, Inc.
Who owns Zevra Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Zevra Therapeutics, Inc.: Fmr LLC (9.4%, Schedule 13G/A, filed 2026-11-05), Woodline Partners LP (8.1%, Schedule 13G/A, filed 2026-08-14) and Vanguard Capital Management (5.11%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of Zevra Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Zevra Therapeutics, Inc. on this page are Fmr LLC (9.4%), Woodline Partners LP (8.1%) and Vanguard Capital Management (5.11%).
When did Fmr LLC buy into Zevra Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-05-06, reporting 5.5%; its latest, Schedule 13G/A filed 2026-11-05, reports 9.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Zevra Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Zevra Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zevra Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-03-09 | Justin Renz | Chief Financial Officer | appointed | 2026-03-09 |
Which insiders own Zevra Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 417,225 shares (0.70% of shares outstanding) (Form 4, 2026-10-13).
- R. LaDuane Clifton: 143,515 shares (0.24% of shares outstanding) (Form 4, 2026-01-07).
- , a director: 123,400 shares (0.21% of shares outstanding) (Form 4, 2026-03-26).
- , the chief commercial officer: 62,278 shares (0.10% of shares outstanding) (Form 4, 2026-02-04).
- , the chief legal and compliance: 37,569 shares (0.06% of shares outstanding) (Form 4, 2026-08-17).
Shares outstanding: 59,504,621 as of 2026-10-30, from the company's latest SEC cover page.
How much has Zevra Therapeutics, Inc. raised?
No fundraising or offering filing from Zevra Therapeutics, Inc. is on file with us.
Keep reading
More on Zevra Therapeutics, Inc. and the records around it.
Zevra Therapeutics, Inc. elsewhere on the record
- Leadership changes Mar 2026
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Adage Capital Management, L.P. also filed stake reports on 161 other companies: Ares Acquisition Corp III (Nov 2026), Avidbank Holdings, Inc. (Nov 2026), B&R Technology Merger Corp. (Nov 2026)
- FMR LLC also filed stake reports on 762 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/zevra-therapeutics